1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Adrenocortical Hyperfunction: new trials by email Literature Review of Adrenocortical Hyperfunction trials Research Report on Adrenocortical Hyperfunction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study. Baxdrostat, Placebo - Primary Hyperaldosteronism | Phase 3 | Active not recruiting | AstraZeneca | 212 | 2025-08-07 | 2026-10-16 |
Adrenal Gland Diseases (1) · Endocrine System Diseases (1)
AstraZeneca (1)
Australia (1) · Canada (1) · China (1) · France (1) · Germany (1) · India (1) · Italy (1) · Japan (1) · Spain (1) · Taiwan (1) · United Kingdom (1) · United States (1)